Vestal Point Capital LP Takes $13.76 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Vestal Point Capital LP purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 990,000 shares of the company's stock, valued at approximately $13,761,000. Vestal Point Capital LP owned about 1.96% of Tyra Biosciences as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in shares of Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE bought a new position in shares of Tyra Biosciences in the 4th quarter valued at $50,000. BNP Paribas Financial Markets bought a new position in shares of Tyra Biosciences in the 4th quarter valued at $60,000. Aquatic Capital Management LLC bought a new position in shares of Tyra Biosciences in the 4th quarter valued at $64,000. Finally, Wells Fargo & Company MN raised its position in Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after purchasing an additional 3,236 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Stock Down 3.1%

Tyra Biosciences stock traded down $0.30 during trading hours on Friday, reaching $9.29. 189,305 shares of the company's stock were exchanged, compared to its average volume of 263,849. The firm's 50 day simple moving average is $9.43 and its 200 day simple moving average is $12.62. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60. The firm has a market capitalization of $493.21 million, a PE ratio of -5.77 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wedbush reaffirmed an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Piper Sandler assumed coverage on Tyra Biosciences in a research report on Wednesday. They set an "overweight" rating and a $33.00 target price for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.